Latest statistics and disclosures from Broadfin Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are Biolinerx Ltd-spons. These five stock positions account for 100.00% of Broadfin Capital's total stock portfolio.
- Added to shares of these 1 stocks: Biolinerx Ltd-spons (+$5.36M).
- Started 1 new stock positions in Biolinerx Ltd-spons.
- Reduced shares in these 10 stocks: IWM (-$436.80M), Horizon Pharma (-$142.02M), Nevro (-$83.83M), FLML (-$71.67M), Retrophin (-$63.00M), (-$62.25M), Heron Therapeutics (-$57.63M), PGNX (-$51.20M), (-$46.21M), (-$31.64M).
- Sold out of its positions in Adma Biologics, ARAY, Advaxis, Aegerion Pharmaceuticals, AMRN, Amphastar Pharmaceuticals, Ampliphi Biosciences, ANGO, AIS, Anthera Pharmaceutcls.
- As of Sept. 30, 2015, Broadfin Capital has $5.36M in assets under management (AUM). Assets under management dropped from a total value of $1.79B to $5.36M.
- Independent of market fluctuations, Broadfin Capital was a net seller by $1.79B worth of stocks in the most recent quarter.
Broadfin Capital portfolio companies for September 2015 quarter
|Ticker||Name||Portfolio Weight||Change||Share Count||Price||Last Trade|
Past 13F-HR SEC Filings for Broadfin Capital
- Broadfin Capital 2015 Q3 - filed Nov. 16, 2015
- Broadfin Capital 2014 Q4 - filed Feb. 17, 2015
- Broadfin Capital 2014 Q4 amended - filed Feb. 17, 2015
- Broadfin Capital 2014 Q2 amended - filed Aug. 22, 2014
- Broadfin Capital 2014 Q2 - filed Aug. 14, 2014
- Broadfin Capital 2013 Q4 amended - filed Feb. 28, 2014
- Broadfin Capital 2013 Q3 - filed Nov. 14, 2013
- Broadfin Capital 2012 Q4 - filed Feb. 14, 2013
- Broadfin Capital 2012 Q3 - filed Nov. 14, 2012
- Broadfin Capital 2012 Q1 - filed May 15, 2012
- Broadfin Capital 2011 Q4 - filed Feb. 13, 2012
- Broadfin Capital 2011 Q3 - filed Nov. 14, 2011
- Broadfin Capital 2011 Q2 - filed Aug. 15, 2011
- Broadfin Capital 2011 Q1 - filed May 16, 2011
- Broadfin Capital 2010 Q4 - filed Feb. 14, 2011